Disease · MONDO_0004670
lupus erythematosus
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. lupus erythematosus. Diseases, record MONDO_0004670. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004670
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Phase 3, for 4 of its 15 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ENPATORAN | CHEMBL4802159 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ABETIMUS SODIUM | CHEMBL2108835 | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets | |
| LAQUINIMOD | CHEMBL66092 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VOCLOSPORIN | CHEMBL5314379 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ABROCITINIB | CHEMBL3655081 | Small molecule | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
| ATACICEPT | CHEMBL1742986 | Protein | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
| NARSOPLIMAB | CHEMBL4298195 | Antibody | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
| PAQUINIMOD | CHEMBL67776 | Small molecule | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets19
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| JAK1 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| CD74 | HLA class II histocompatibility antigen gamma chain | 1 | HLA-DR antigens-associated invariant chain antagonist | Phase 1 | https://conductscience.org/library/genes/972 | Drugs and targets |
| IFNB1 | Interferon beta | 1 | Interferon beta inhibitor | Phase 1 | https://conductscience.org/library/genes/3456 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 2 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 2 | https://conductscience.org/library/genes/3615 | Drugs and targets |
| IRAK4 | Interleukin-1 receptor-associated kinase 4 | 1 | Interleukin-1 receptor-associated kinase 4 inhibitor | Phase 1 | https://conductscience.org/library/genes/51135 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 1 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 1 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| MASP2 | Mannan-binding lectin serine protease 2 | 1 | Mannan-binding lectin serine protease 2 inhibitor | Phase 2 | https://conductscience.org/library/genes/10747 | Drugs and targets |
| OPRD1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 1/2 | https://conductscience.org/library/genes/4985 | Drugs and targets |
1 to 10 of 19
See all 19 targetsTrials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05306873 | Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus | Phase 2 | 12 | 2025-09-09 | Systemic Lupus Erythematosus | MYCOPHENOLATE MOFETIL, VOCLOSPORIN | Its record names the disease | ClinicalTrials.gov |
| NCT07332481 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease | Phase 3 | 202 | Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | ENPATORAN | Its record names the disease | ClinicalTrials.gov | |
| NCT07355218 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | Phase 3 | 202 | Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus | ENPATORAN | Its record names the disease | ClinicalTrials.gov | |
| NCT07221565 | Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT) | Phase 1/2 | 120 | Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation | NALTREXONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00005778 | High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide | Phase 3 | 100 | Lupus Erythematosus, Systemic | CYCLOPHOSPHAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01845740 | Phase Ib Study of SC Milatuzumab in SLE | Phase 1 | 22 | Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Lupus Nephritis | MILATUZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06238531 | A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus | Phase 1 | 0 | Systemic Lupus Erythematosus | GUSACITINIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Stage 2 MMF vs Stage 2 Placebo for MMF: The Percentage of Participants Who Experience a Stage 2 Treatment Failure at or Before the Stage 2 Week 24 Visit. | 2 of 4 | 2 of 4 | 8 | NCT05306873 | Trial comparisons |
| Stage 2 MMF vs Stage 2 Placebo for MMF: The Incidence of Grade 3 or Higher Infections in Stage 2 | 0 of 4 | 1 of 4 | 8 | NCT05306873 | Trial comparisons |
| Stage 2 MMF vs Stage 2 Placebo for MMF: The Incidence of Grade 3 or Higher Hypertension in Stage 2 | 0 of 4 | 0 of 4 | 8 | NCT05306873 | Trial comparisons |
| Stage 2 MMF vs Stage 2 Placebo for MMF: The Incidence of Grade 3 or Higher Related Adverse Events (AEs) in Stage 2 | 0 of 4 | 0 of 4 | 8 | NCT05306873 | Trial comparisons |
| Stage 2 MMF vs Stage 2 Placebo for MMF: The Incidence of Renal Dysfunction in Stage 2 | 0 of 4 | 0 of 4 | 8 | NCT05306873 | Trial comparisons |
| Stage 3 MMF + Voclosporin vs Stage 3 MMF + Placebo for Voclosporin: The Incidence of Grade 3 or Higher Hypertension in Stage 3 | 0 of 2 | 0 of 1 | 3 | NCT05306873 | Trial comparisons |
| Stage 3 MMF + Voclosporin vs Stage 3 MMF + Placebo for Voclosporin: The Incidence of Grade 3 or Higher Related Adverse Events (AEs) in Stage 3 | 0 of 2 | 0 of 1 | 3 | NCT05306873 | Trial comparisons |
| Stage 3 MMF + Voclosporin vs Stage 3 MMF + Placebo for Voclosporin: The Incidence of Renal Dysfunction in Stage 3 | 0 of 2 | 0 of 1 | 3 | NCT05306873 | Trial comparisons |
Stage 3 MMF + Voclosporin vs Stage 3 MMF + Placebo for Voclosporin: The Proportion of Participants Who Experience a Stage 3 Treatment Failure, After Stage 3 Re-randomization at or Before Completing Stage 3 Week 24. | 0 of 2 | 1 of 1 | 3 | NCT05306873 | Trial comparisons |
| Stage 3 MMF + Voclosporin vs Stage 3 MMF + Placebo for Voclosporin: The Incidence of Grade 3 or Higher Infections in Stage 3 | 0 of 2 | 0 of 1 | 3 | NCT05306873 | Trial comparisons |
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004670
GET https://conductscience.org/api/diseases/v1/MONDO_0004670/drugs